What smart money is saying about McKesson Corporation
3 funds in our archive have pitched McKesson Corporation — most recently Aristotle Global Equity Strategy in September 2026.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q3 2026, 10 fund letters reported a position in McKesson Corporation — 6 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 2 | 2 | 0 | 1 |
| Q2 2026 | 4 | 3 | 0 | 1 |
| Q1 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 1 | 0 | 0 | 0 |
| Q2 2025 | 1 | 1 | 0 | 0 |
| Q1 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 1 | 0 | 0 | 0 |
Fund activity · 10 positions · 6 moves
- New positionAristotle Global EquitySeptember 2026
“During the quarter, we sold our positions in Assa Abloy and Oshkosh and purchased E Ink Holdings and McKesson.”
McKesson Corporation - New positionAristotle Global Equity StrategySeptember 2026
“During the quarter, we sold our position in Assa Abloy and purchased E Ink Holdings and McKesson.”
McKesson Corporation - AddedAlluvium Global Fund ConventumJune 2026
“McKesson, the drug distributor (down 12.6%), reported its full year results which were perfectly in-line with our expectations. Management provided strong guidance for its next year’s earnings, and reiterated its 13%-16% long term growth expectations. After feeding the numbers through our model, our valuation increased by 18%, and with the share price trading below it, we bought a little more such that it accounts for 6.8% of the Fund.”
McKesson Corporation - AddedAlluvium AM ConventumJune 2026
“McKesson, the drug distributor (down 12.6%), reported its full year results which were perfectly in-line with our expectations. Management provided strong guidance for its next year’s earnings, and reiterated its 13%-16% long term growth expectations. After feeding the numbers through our model, our valuation increased by 18%, and with the share price trading below it, we bought a little more such that it accounts for 6.8% of the Fund.”
McKesson Corporation - New positionAppalaches Capital Appalaches Core LOJune 2026
“We have had the opportunity to invest in a couple of new businesses this quarter, and the great opportunity to invest more in some of our current holdings. We increased our stakes in AutoZone, CME Group, and Progressive. We also made a new investment in McKesson Corporation and had other smaller purchases.”
McKesson Corporation - June 2026
Listed in Munro Concentrated Global Growth Fund’s reported holdings.
McKesson Corporation - HoldsAlluvium Global FundMarch 2026
“For HCA, management announced an increase to its dividend and increased buybacks, and the share price spiked 7.1% on the day. We updated our valuations. In the case of HCA, it increased about 30%, with half being attributable to our revised maintainable earnings estimates and the other half being a result of revisiting our view of its business risks. For McKesson, these were not full year results and we only made a couple of tweaks which increased our valuation by around 5%. Both remain sizeable positions in the Fund, at 6.6% and 6.0% respectively.”
McKesson Corporation - December 2025
Listed in Sands Capital Global Leaders’s reported holdings.
McKesson Corporation - New positionLatitude IMJune 2025
“An example would be our sale of Novo Nordisk in 2022, a business which we highly admire and would happily invest in in the future but felt our investors capital was better recycled at that valuation into another shelf stock: McKesson.”
McKesson Corporation - HoldsNewBridge Large Cap Growth EquityDecember 2024
“Within Health Care , McKesson rebounded in the fourth quarter after a challenging third quarter and was the sector’s best performer within the portfolio.”
McKesson Corporation
Also mentioned · 1
These funds discuss McKesson Corporation — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedBristolgate U.S. Equity StrategyJune 2026
“Detractors Intuit was the largest detractor with the share price down significantly after its quarterly report disappointed investors. This compounded fears that parts of its business could be disrupted by AI. After a strong first quarter, Mckesson’s share price weakened after its report that surfaced concerns regarding growth from GLP-1s.”
McKesson Corporation
Fund coverage · 3 theses
- Aristotle Global Equity StrategySeptember 2026
McKesson Corporation is a leading U.S. pharmaceutical distributor with mission-critical scale, switching costs and growth in higher-margin healthcare services.
Read the full thesis - Appalaches Core LOJune 2026
McKesson benefits from its dominant drug distribution role, structural barriers to entry, improving generic and biosimilar economics, high ROIC, and an attractive valuation.
Read the full thesis - Baron Health Care FundMarch 2025
McKesson Corporation is evolving into a diversified health care services company with strong positions in oncology and biopharmaceutical services, aiming for 12% to 14% annual earnings per share growth.
Read the full thesis
Read every full thesis on McKesson Corporation
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→